A Fleet of Analyzers Keeps Work Flowing by SCIEX Community | 0 CommentsAn Interview with Timothy Sangster, Head of Bioanalysis and Immunology, Charles River Laboratories, Edinburgh
Delivering New Biologics to the Marketplace by SCIEX Community | 0 CommentsCharacterization and quantification of host cell proteins (HCPs) in biopharmaceutical development and manufacturing is a critical step to ensuring product safety. While this can be achieved using ELISA, mass spectrometry using the SCIEX TripleTOF® 6600 System is more specific and enables the identification and quantitation of each of the individual proteins present.
Speeding the Development of Quantitative Biosimilar Assays by SCIEX Community | 0 CommentsWhen developing new quantitative assays for Biotherapeutics, every biologic requires a specific sample prep strategy, which includes sourcing reagents and research protocols. However, as every bioanalytical lab knows all too well, it can also take up to two months to develop an optimized and robust LC-MS assay. For this reason, researchers understandably want an easier way to develop highly sensitive and specific assays for biotherapeutics and biosimilars to accelerate sample turnaround time.
Do You Want to Accelerate Quantitative Assays for Antibody Drug Conjugates? by SCIEX Community | 0 CommentsAre you tasked with the bioanalysis of antibody drug conjugates (ADCs)? If so, you know they represent a rapidly growing class of biotherapeutics, but their unique chemical structure makes quantitative analysis particularly challenging.
The whys behind the dos and don’ts of oligonucleotide analysis by Kerstin Pohl | Biopharma, Blogs, PharmaWe know that LC-MS oligonucleotide analysis can have its share of challenges—challenges with sensitivity, challenges with adduct formation and challenges with data analysis, to name just a few. That’s why this blog takes a closer look at the dos and don’ts of this type of analysis and explores some keys to success. It also explains why following these simple rules can vastly improve your oligonucleotide characterization and quantitation efficiency and success.
Top 7 Echo® MS system customer questions—answered by Neil Walsh | Biopharma, Blogs, Echo MS, Pharma You asked, we answered! With analysis speeds of at least 1 sample per second, the Echo® MS system has created a buzz in the industry. This is up to 50x faster than conventional LC-MS/MS. This revolutionary tool for drug discovery and development has led to...
An interview from the Science Explorer about the Echo® MS system by SCIEX Community | Blogs, Echo MS, PharmaThe Science Explorer interviews Neil Walsh from SCIEX to discuss the significant application areas of the Echo® MS System and what makes this system so attractive to biopharmaceutical laboratories.
The Echo® MS system: Is it reproducible? Yes… yes… yes! by Neil Walsh | Biopharma, Blogs, Echo MS, PharmaThe Echo® MS System is an exciting new platform that dramatically speeds sample analysis for quantitative MS studies. Because of its unique and innovative technology, the system can analyze samples faster than ever before—but without the need for LC.
Scale it up! The Echo® MS System delivers unprecedented levels of productivity by Neil Walsh | Biopharma, Blogs, Echo MS, PharmaImagine the productivity gains your lab could achieve with a technology that not only analyzes samples up to 50x faster than conventional quantitative LC-MS, but also eliminates tedious sample preparation, time-consuming LC method development and chromatographic run...
How fast is fast? The Echo® MS System sets the record by Neil Walsh | Biopharma, Blogs, Echo MS, PharmaHow fast is fast? Cheetahs. Usain Bolt. Tachyons. The Echo® MS system. What do these things have in common? They’re all fast. REALLY fast. In fact, they’re the fastest in their categories: the fastest land mammal, the fastest human sprinter, the fastest subatomic...
A new generation of therapeutic modalities by SCIEX Community | Biopharma, Blogs, PharmaThere are over 7,000 genetic diseases that could potentially be cured using gene therapy. Rare metabolic diseases, autoimmune disorders, cardiovascular disease and cancers are some of the top disease classes that can be addressed with gene therapies. With over 1,000...
Enhancing Biologics with CESI-MS Characterization by SCIEX Community | Biopharma, BlogsComprehensive characterization of a biologic requires analysis at both the intact and digest levels, but these analyses can be complex and cumbersome. For example, with conventional liquid chromatography separations, researchers are often left with limited information...
Full, partial and empty capsid ratios for AAV analysis: What’s the big deal? by SCIEX Community | Biopharma, Blogs, PharmaFor many of you working to develop gene therapy drugs, you know that the time to market the drug is critical. Because gene therapeutics cure diseases by targeting specific genes, it is a constant race to see who develops the drug first. Unlike other classes of drugs where multiple medications can be used to treat a disease, whoever is first to develop a gene therapy drug wins.
Ever thought of breaking the high-throughput sound barrier for drug discovery? by SCIEX Community | Blogs, PharmaWouldn’t it be great if we really could “get time back” or even “buy time”? When developing pharmaceuticals, it takes years to bring a new therapy to the market due to the linear nature of the process. As the saying goes, “Time waits for no one.” But what if we could...